The NHS is about to light billions of pounds on fire to subsidize a biological bypass for poor lifestyle choices.
The headlines are glowing. They promise a "miracle" rollout of semaglutide (Wegovy) to thousands of patients at risk of recurring heart attacks. It sounds like a victory for public health. It sounds like progress.
It is actually a white flag.
By expanding the use of GLP-1 receptor agonists to cardiac patients, the UK government isn’t "preventing" heart disease. It is outsourcing human metabolism to a Danish pharmaceutical giant while the underlying causes of the UK's obesity crisis continue to rot the system from within. We are treating the symptom of a broken food environment with a lifelong subscription to a chemical stabilizer.
The SELECT Trial Illusion
The logic behind this NHS expansion rests largely on the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events (MACE) for overweight or obese patients with established heart disease.
Twenty percent.
In clinical terms, that is significant. In practical, systemic terms, it is a rounding error compared to the efficacy of actual metabolic health. The trial didn't show that Wegovy "cures" heart disease. It showed that if you take a population with already ravaged arteries and force their bodies to process glucose slightly better while suppressing their appetite, they die slightly less often over a five-year period.
What the "lazy consensus" ignores is the Number Needed to Treat (NNT). To prevent a single cardiovascular event, you have to medicate dozens of people for years at a staggering cost. When the NHS scales this to "hundreds of thousands" of people, the math stops working. We are looking at a permanent line item in the budget that grows every year, because these drugs are not a course of antibiotics. They are a chronic intervention. Stop the jab, and the weight—and the cardiac risk—returns with a vengeance.
The Muscle-Wasting Secret
Here is the nuance the mainstream media won't touch: semaglutide is a blunt instrument.
When you lose weight on a GLP-1, you aren’t just losing fat. You are losing lean muscle mass at an alarming rate. For a 25-year-old influencer, that’s a vanity issue. For a 65-year-old heart attack survivor, muscle loss is a death sentence. Sarcopenia—the loss of muscle tissue—is a primary driver of frailty and all-cause mortality in the elderly.
The NHS is essentially trading cardiovascular risk for frailty risk. We are creating a generation of "thin-fat" cardiac patients who have less cardiac strain but also less physical capacity to survive a fall, a bout of pneumonia, or a subsequent surgery. We are optimizing for a single metric—Weight—while ignoring the total biological cost.
The Economics of Dependency
Let’s talk about the "battle scars" of healthcare procurement. I have watched the NHS get locked into "innovative" drug cycles before. It starts with a restricted rollout for the "most at risk." Then the criteria widen. Then the price stays high because the demand is inelastic.
Novo Nordisk isn't a charity. They are a $500 billion company. By integrating Wegovy into the standard of care for cardiac recovery, the NHS is handing over the keys to its budget.
Imagine a scenario where 10% of the UK population is on a GLP-1. At current negotiated prices, that would consume a terrifying chunk of the total NHS pharmaceutical budget. This is money stripped away from:
- Primary care infrastructure.
- Surgical backlog reduction.
- Mental health services.
- Actual nutritional education in schools.
We are choosing to pay for the "cure" rather than fixing the poison. The UK food system is an ultra-processed nightmare. We subsidize the cheap carbohydrates that cause the inflammation, which causes the obesity, which causes the heart attack. Then, we use taxpayer money to buy the drug that mitigates the damage. It is a closed loop of fiscal insanity where the only winners are Big Food and Big Pharma.
The "Prevention" Lie
The most offensive part of this rollout is calling it "preventative."
Preventative medicine happens in the grocery store, the gym, and the urban planning office. Putting a heart attack survivor on a weekly injection is reactive medicine. It is damage control.
If we were serious about heart health, we would be talking about:
- ApoB Testing: Not just standard cholesterol panels, but deep-dive lipidomics to identify real risk before the first plaque forms.
- Zone 2 Training: Building mitochondrial health that no drug can replicate.
- Protein Prioritization: Ensuring cardiac patients don't wither away while the drug suppresses their desire to eat.
Instead, we provide a needle. It’s easier for a GP to write a script than it is to coach a patient through a total life overhaul. It’s easier for a politician to announce a "new wonder drug" than to take on the lobbyists who keep high-fructose corn syrup and seed oils in every school lunch.
The Hidden Cost of Compliance
The NHS expects people to stay on these drugs indefinitely. They won’t.
Real-world data on GLP-1 adherence is abysmal. Within a year, a massive percentage of patients drop off due to nausea, gastroparesis (stomach paralysis), or simple "needle fatigue." When they drop off, their metabolism is often in a worse state than when they started because they’ve lost the muscle mass that previously burned calories at rest.
The "rebound" heart attack is the ghost in the machine that no one is planning for. We are setting up a volatility trap. By relying on a drug to maintain cardiac stability, we make the patient's heart health dependent on global supply chains and government funding cycles. If the drug goes out of stock—as it has for the last two years—the patient’s risk profile doesn’t just return to baseline; it spikes.
Stop Treating the Patient Like a Passenger
The competitor article treats the NHS patient as a passive recipient of "healthcare." This is the fundamental flaw. Health is an active pursuit.
By medicalizing obesity as a "chronic disease" that requires a permanent pharmaceutical fix, we are stripping away the agency of the individual. We are telling them their biology is broken and only a multi-billion dollar corporation can fix it.
I’ve seen what happens when you give people the "easy way out." They take the jab, they lose the weight, and they continue to sit on the couch eating the same inflammatory foods because their "numbers" look better on paper. Their visceral fat—the dangerous stuff around the organs—might shrink, but their metabolic flexibility remains zero.
The Brutal Truth
This NHS rollout isn't a breakthrough; it’s a bailout for a failed public health strategy.
We have allowed our population to become so metabolically crippled that our only remaining option is to put the nation on a permanent chemical drip. It is an admission that we have lost the war against ultra-processed food and sedentary lifestyles.
If you think this is about "saving lives," you’re looking at the wrong ledger. This is about managing the decline of a population while ensuring the profits of the medical-industrial complex remain "robust."
If you want to survive a heart attack, get off the couch, eat a steak, and lift something heavy. If you want to be a data point in a pharmaceutical sales deck, wait for your NHS invitation.
The needle is a leash. Stop pretending it’s a cure.
